CORMEDIX INC.

CRMD
Delayed Quote. Delayed  - 05/17 04:00:01 pm
3.82USD +5.82%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Specialty & Advanced Pharmaceuticals
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

Number of employees : 30 people.
Sales per Business
20202021
Therapeutic Products0.24100%0.19100%
USD in Million
Sales per region
20202021
Germany0.2499.1%0.19100%
United States0.000.9%--
USD in Million
Managers
Name Title
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Phoebe Mounts EVP, General Counsel, Head-Regulatory & Compliance
Janet D. Dillione Independent Director
Steven W. Lefkowitz Independent Director
Alan W. Dunton Independent Director
Paulo F. Costa Independent Director
Shareholders
Name Equities %
Nomura Securities Co., Ltd. (Private Banking) 2,003,612 5.17%
The Vanguard Group, Inc. 1,778,236 4.59%
Elliott Investment Management LP 1,550,523 4.00%
BlackRock Fund Advisors 879,058 2.27%
Credit Suisse Securities (USA) LLC (Broker) 754,757 1.95%
SSgA Funds Management, Inc. 701,822 1.81%
Geode Capital Management LLC 643,458 1.66%
Northern Trust Investments, Inc.(Investment Management) 335,963 0.87%
Cresset Asset Management LLC 329,796 0.85%
Sabby Capital LLC 249,198 0.64%
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capi. (M$)
CORMEDIX INC.-20.66%141
MERCK KGAA-29.07%72 825
KYOWA KIRIN CO. LTD.-11.77%11 512
SK BIOPHARMACEUTICALS CO., LTD.-8.95%5 416
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.83.44%3 122
YUHAN CORPORATION-6.92%3 069
BETTA PHARMACEUTICALS CO., LTD.-46.17%2 688
INDIVIOR PLC15.56%2 562
SUPERNUS PHARMACEUTICALS, INC.-5.90%1 465
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.-37.82%1 333
KISSEI PHARMACEUTICAL CO., LTD.11.71%899
HK INNO.N CORPORATION-25.24%863
OSCOTEC INC.-31.83%591
EAGLE PHARMACEUTICALS, INC.-11.29%574
KNIGHT THERAPEUTICS INC.-1.89%464
DONG-A ST CO., LTD.-8.66%430
GULF PHARMACEUTICAL INDUSTRIES P.S.C.-32.07%399
CALLIDITAS THERAPEUTICS AB (PUBL)-35.02%386
HBM HOLDINGS LIMITED-53.81%321
SCI PHARMTECH, INC.-2.74%260
CANBRIDGE PHARMACEUTICALS INC.-54.96%200
Brand Portfolio
» More brands of CorMedix Inc.